ALPHARETTA, Ga.--SANUWAVE Health, Inc., (OTCBB: SNWV) (, an emerging medical technology company focused on regenerative medicine, will participate in the Rodman & Renshaw Annual Global Investment Conference taking place September 13-15, 2010 at the Palace Hotel in New York City.

Christopher M. Cashman, President and CEO of SANUWAVE, will present a corporate update on Wednesday, September 15, 2010 at 10:50 a.m. Eastern Time in which he will discuss an overview of SANUWAVE, including an update on its FDA-approved Phase III, pivotal, Investigational Device Exemption (IDE) clinical trial for the treatment of diabetic foot ulcers that completed patient enrollment in the first quarter of 2010, as well as its strategic initiatives in the wound care, orthopedic and aesthetic market segments. The Phase III IDE clinical trial is evaluating Pulsed Acoustic Cellular [removed]PACE™) technology and the safety and efficacy of the Company’s lead product, dermaPACE™, in healing diabetic foot ulcers compared to standard of care. Top line results from this pivotal trial are expected in the fourth quarter, and the Company plans to file a Premarket Approval Application (PMA) not later than first quarter 2011.

Company management will be available for one-on-one meetings with investors participating in the Rodman & Renshaw Conference. For those who would like to schedule an appointment with SANUWAVE’s management, please contact Anne Marie Fields, Lippert/Heilshorn & Associates, Inc., at 212-838-3777 or at, or contact your Rodman & Renshaw representative.

The presentation will be webcast live at where it will also be archived for 90 days.

About SANUWAVE Health, Inc.

SANUWAVE Health, Inc. ( is an emerging regenerative medicine company focused on the development and commercialization of non-invasive, biological response activating devices for the repair and regeneration of tissue, musculoskeletal and vascular structures. SANUWAVE’s portfolio of products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body’s normal healing processes and regeneration. SANUWAVE intends to apply its Pulsed Acoustic Cellular [removed]PACE™) technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE™, is CE marked for treatment of the skin and subcutaneous soft tissue and has completed enrollment in its FDA-approved Phase III, pivotal, Investigational Device Exemption (IDE) trial in the U.S. for the treatment of diabetic foot ulcers (DFU). SANUWAVE researches, designs, manufactures, markets and services its products worldwide and believes it has already demonstrated that this technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved Ossatron® device, as well as stimulating osteogenesis to regenerate tissue for sports medicine, orthopedic and trauma indications such as tendinopathy, non-union fracture and osteoarthritis through the utilization of its Ossatron®, Evotron™, and recently introduced orthoPACE™, devices in Europe.

Safe Harbor Statement

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.